суббота, 20 февраля 2016 г.

FDA clears expanded use of Pfizer's breast cancer med IBRANCE

FDA clears expanded use of Pfizer's breast cancer med IBRANCE


The FDA approves Pfizer's supplement New Drug Application for IBRANCE . It is now cleared for the treatment of hormone receptor-positive , human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in combination with fulvestrant [AstraZeneca's FASLODEX ] in women with disease progression following endocrine therapy.



from Biotech News